logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

MORSE Consulting Bolsters Private Payer Expertise

September 9, 2020
-
Market Access News, What's New
-
Posted by MORSE - 2 min read.

Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans.

The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers are increasingly considering Canadian Agency for Drugs and Technologies in Health (CADTH) recommendations for reimbursement decision-making. In addition, similar to public payers, many private payers are expecting the negotiation of product listing agreements (PLAs) as a condition for listing. As a result, there is a clear need for companies to better understand this important and rapidly evolving segment of the reimbursement pathway.

With the addition of Sal Cimino, MORSE Consulting now offers strategic advice related to the private payer market. Sal is a pharmacist with considerable experience working in private insurance, community, and hospital pharmacy. He was the Director of Pharmacy Services at Green Shield Canada (GSC) for nearly 20 years and in that role, Sal was instrumental in developing their premier managed formulary. He was also involved in the introduction of the MAC Pricing and the Tiered Drug programs. As co-chair of the Pharmacy & Therapeutics Committee Director, Sal was responsible for new drug submission evaluation and formulary listing decision-making. Recently, he and his team were responsible for the operational facet of the GSC Biosimilar Program. In addition, Sal has a unique understanding of how private payers operationalize product listing agreements.

As a Senior Consultant, Private Drug Plans, Sal will help clients achieve reimbursement success by drawing upon his considerable experience to provide meaningful and actionable insights related to private drug plan coverage.

 

 

With this addition, MORSE Consulting now offers expert, operational understanding of:

  • Health Technology Assessment – Anita Carrie
  • Public drug plans (including cancer programs) and pan-Canadian Pharmaceutical Alliance (pCPA) – Sherry O’Quinn, Brad Alyward, Anita Gadhok and Roy Cairns
  • Private Drug Plans – Sal Cimino

Please contact Arvind Mani (arvind@morseconsulting.ca), Sherry O’Quinn (sherry@morseconsulting.ca) or Brad Alyward (brad@morseconsulting.ca) to discuss how our team can address your market access needs.

 

Share
Tags
CADTH
HTA
Market Access Strategy
MORSE Team
Oncology
pCPA
pCPAO
Pharmacare
Pharmaceuticals
PLA
PLAs
Private Payers
Reimbursement strategy
← PREVIOUS POST
An Uncharacteristically Slow August Gives Way to an Uncertain Fall
NEXT POST →
Impact of COVID19 on pCPA Negotiations Starting to Emerge

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
MORSE Consulting Bolsters Private Payer Expertise